Search Results

P4 Diagnostix®, a network of nationally recognized laboratories (“P4"), will be partnering with Pierian, a global leader in advanced clinical genomics technology and services, to launch somatic testing for prostate cancer patients.

Genome Medical, the leading telehealth provider of genetic services and genomics-based care, and Pierian, the global leader in advanced clinical genomics technology and services, announced a collaboration designed to streamline and optimize onsite genomics programs for health care organizations and provider groups.

Syapse®, a leading real-world evidence company announced with Pierian®, a global leader in advanced clinical genomics technology, a new joint collaboration that will benefit patients of the AdventHealth Cancer Institute in Central Florida.

Arima Genomics, Inc. and Pierian, now a part of Velsera, the precision engine company which enables the democratization of omic data across clinical and research applications, today announced co-marketing and licensing agreements that will provide enhanced gene fusion detecting capabilities to clinical labs.

PierianDx, the global leader in clinical genomics knowledge, announced that it has partnered with Biodesix to provide its interpretation technology platform for use with the Biodesix newly launched GeneStrat NGS™ genomic test, a blood-based tumor profiling test to detect actionable mutations in patients with non-small cell lung cancer.

PierianDx, the global leader in clinical genomics knowledge, announced that it closed on $30 million of new growth capital including equity financing and a term loan facility, which includes access to additional tranches for up to $17.5 million by 2022 and 2023, subject to certain conditions.

Electra Therapeutics, Inc. announced the appointment of Graham Parry, PhD, as Chief Scientific Officer and Kim-Hien Dao, DO, PhD, as Chief Medical Officer.

PierianDx, the global leader in clinical genomics knowledge, announced that it will partner with Florida Cancer Specialists & Research Institute to support expanded access to the highest quality genomic testing on solid tumors and hematologic malignancies and lymph nodes leveraging NGS technology.

Velsera is delighted to formally announce the appointment of Jamie Littlejohns as its Chief Executive Officer, with his tenure commencing on the 1st of March, 2024.